

Article Title: Lack of evidence for interactions between *APOE* and *Klotho* genotypes on cognitive, dementia and brain imaging metrics in UK Biobank.

Authors: Rachana Tank MSc¹, Joey Ward BSc¹, Daniel J. Smith MD¹, Kristin E. Flegal² PhD, Donald M. Lyall PhD¹.

¹Institute of Health & Wellbeing, University of Glasgow, Scotland, UK.

²Institute of Neurosciences and Psychology, University of Glasgow, Glasgow, Scotland, UK.

Corresponding author

Dr. Donald M. Lyall

1 Lilybank Gardens

Institute of Health and Wellbeing

University of Glasgow

G12 8RZ, Glasgow, UK.

Email: Donald.Lyall@Glasgow.ac.uk

Tel: +44 (0) 141 330 8547

Fax: +44 (0) 141 330 1874

Search terms: *Cognitive; dementia; brain; APOE; Klotho.*

Acknowledgements: This research has been conducted using the UK Biobank resource; we are grateful to UK Biobank participants. Thanks to Dr. Breda Cullen for devising exclusion criteria and Dr. Michael A. Belloy for helpful comments on an earlier draft. This project was completed using UK Biobank application 17689 (PI: DML).

Title character count: 132

Text word count: 1295

Abstract word count: 245

Supplementary Tables: 1

References: 17

28 **Abstract**

29 Importance: Recent research has suggested that genetic variation in the *Klotho* (KL) locus
30 may modify the association between apolipoprotein e (*APOE*) e4 genotype and cognitive
31 impairment.

32 Objective: Large-scale testing for associations and interactions between *KL* and *APOE*
33 genotypes vs. risk of dementia (n=1,570 cases), cognitive abilities (n=174,513) and brain
34 structure (n = 13,158) in older (60+ years) participants.

35 Design, setting and participants: Cross-sectional and prospective data (UK Biobank).

36 Main outcomes and measures: *KL* status was indexed with heterozygosity of the rs9536314
37 polymorphism (vs. not), in unrelated people with vs. without *APOE* e4 genotype, using
38 regression and interaction tests. We assessed non-demented cognitive scores (processing
39 speed; reasoning; memory; executive function), multiple structural brain imaging, and clinical
40 dementia outcomes. All tests were corrected for age, sex, assessment centre, eight principal
41 components for population stratification, genotypic array, smoking history, deprivation, and
42 self-reported medication history.

43 Results: *APOE* e4 presence (vs. not) was associated with increased risk of dementia, worse
44 cognitive abilities and brain structure differences. *KL* heterozygosity was associated with
45 less frontal lobe grey matter. There were no significant *APOE/KL* interactions for cognitive,
46 dementia or brain imaging measures (all $P > 0.05$).

47 Conclusions and relevance: We found no evidence of *APOE/KL* interactions on cognitive,
48 dementia or brain imaging outcomes. This could be due to some degree of cognitive test
49 imprecision, generally preserved participant health potentially due to relatively young age,
50 type-1 error in prior studies, or indicative of a significant age-dependent *KL* effect only in the
51 context of marked AD pathology.

52

53 **Key points**

- 54 • **Question:** *Klotho* genotype has been previously shown to 'offset' a substantial amount of
55 the *APOE* e4/cognitive impairment association. Is this modification effect apparent in
56 large-scale independent data, in terms of non-demented cognitive abilities, brain
57 structure and dementia prevalence?
- 58 • **Findings:** In aged 60 years and above participants from UK Biobank, we found
59 significant associations of *APOE* and *Klotho* genotypes on cognitive, structural brain and
60 dementia outcomes, but no significant interactions.
- 61 • **Meaning:** This could reflect somewhat healthy participants, prior type 1 error or
62 cognitive/dementia ascertainment imprecision, and/or that *Klotho* genotypic effects are
63 age and neuropathology dependent.

64 Introduction

65 Preserving cognitive abilities such as memory is a common concern into older age, and in
66 the absence of reliable treatments, the public health priority is prevention and delay of
67 cognitive impairment¹, including understanding effect modifiers. *APOE* e4 is a known risk
68 factor for AD and cognitive decline¹. Genetic variation in the *KL* locus has been associated
69 with ageing-related phenotypes including insulin resistance and brain function². A recent
70 study of AD cohorts, longitudinal conversion and amyloid-beta samples showed a
71 statistically significant 'modification' effect where the deleterious effects conferred by *APOE*
72 e4 were offset by heterozygosity based on two *KL* polymorphisms in strong linkage
73 disequilibrium: F352V (rs9536314) and C370S (rs9527025), possibly due to correlations with
74 increased serum Klotho³. UK Biobank is a relatively large general population cohort⁴ where
75 we have previously shown deleterious effects of *APOE* e4 on cognitive⁵, structural brain
76 imaging⁶ and AD/dementia phenotypes⁷. This brief report tested the hypothesis that based
77 on recent research, genetic *KL* variation would interact with *APOE* e4 genotype in relevant
78 cognitive, brain and dementia phenotypes.

79

80 Methodology

81 Study design and participants

82 UK Biobank is a prospective cohort study including 502,628 participants who attended one
83 of 22 baseline assessment centres from 2006 to 2010, aged 40-70 years⁸. In 2014, MRI
84 scanning of a sub-group of 100,000 participants began, and this is ongoing. This analysis
85 was conducted under generic approval from the NHS National Research Ethics Service
86 (approval letter dated 17th June 2011, ref 11/NW/0382). Written informed consent was
87 obtained from all participants in the study.

88 Dementia outcomes

89 Dementia/AD outcomes were generated using self-report, hospital admission and death
90 record data, with data utilising International Classification of Diseases version 10 (ICD-10
91 codes). Individuals were designated as cases (“all-cause dementia” or “Alzheimer disease”) if they had indicated either in self-report or hospital/death records – derived by UK
92 Biobank^{7,9}. Those coded as missing were designated as controls (i.e. did not self-report
93 dementia, and diagnoses not present in hospital/death records).

95

96 Imaging data

97 The release of brain MRI data as of July 2020 was used (i.e. approximately 40k). All imaging
98 data used here was processed and quality checked by UK Biobank¹⁰. We selected imaging
99 phenotypes *a priori* shown to be associated with worse cognitive ability and decline total
100 white and grey volumes adjusted for skull size (WM/GM respectively); log WM
101 hyperintensity volume (WMH); overall hippocampal volume; general factors of fractional
102 anisotropy (FA) and mean diffusivity (MD), and frontal lobe GM (gFrontal)¹¹ based on
103 principal components analysis (PCA). Total WM hyperintensity volumes were calculated
104 based on T1 and T2 fluid-attenuated inversion recovery (FLAIR), derived by UK Biobank.

105

106 Cognitive data

107 Five tests were completed at baseline (2006-2010), of which we examine three here which
108 have shown sufficient intra-participant reliabilities: Pairs-matching 6-pair (memory), verbal-
109 numeric reasoning and log reaction time (processing speed)¹². We also examined four
110 cognitive tests administered from 2014 onwards. These were: Trail making test a+b
111 (processing speed/executive function) and Digit symbol substitution (executive function)
112 assessed via online follow-up, plus Matrix pattern completion (nonverbal reasoning) and
113 Tower rearranging (executive function) at MRI¹¹.

114

Genetic data

UK Biobank genotyping was conducted by Affymetrix using a bespoke BiLEVE Axiom array for ~50,000 participants and the remaining ~450,000 on the Affymetrix UK Biobank Axiom array. All genetic data were quality controlled by UK Biobank as described by the protocol paper⁴). *APOE* e4 'risk' genotype presence (vs. non-e4) was genotyped based on rs7412 and rs429358. KL was indexed using rs9536314 where G/T is considered protective (vs. G/G; T/T) and synonymous with KL-VS diplotype heterozygosity¹³.

Covariates

Participants self-reported their smoking history: current, past or never, medication use for dyslipidaemia, hormone replacement therapy, blood pressure, oral contraceptive or insulin. We excluded participants for whom these data were missing (<5%). Townsend deprivation indices were derived from postcode of residence.

Statistical analysis

PLINK v1.90 was used for genetic quality controlling and Stata V.14 was used for statistical analyses. We removed participants who reported neurological conditions as described previously¹². We statistically controlled for: age, sex, Townsend, ever-smoking, genotypic array, baseline/MRI assessment centre, 8 principal components, array, and medication (concurrent to the phenotype under study; dementia outcomes used baseline values). We focussed on participants aged ≥60 years at baseline³. We excluded participants with non-white British ancestry, self-report vs. genetic sex mismatch, putative sex chromosomal aneuploidy, excess heterozygosity, and missingness rate >0.1. We accounted for relatedness between participants by removing one random participant in cases where two individuals were 1st cousins or closer. We have previously reported power calculations indicative of >95% confidence to find 'true' effect sizes at Cohen's D = 0.1 (i.e. small) with regard to *APOE* genotype and outcomes in UK Biobank⁶.

Results

Descriptives

After exclusions there were baseline N=174,513 (mean age 64.1, SD=2.85) participants; imaging n=13,158 (72.24 years; SD 3.31). For rs9536314 there were 47,593 heterozygotes (G/T; 27%), and N=46,270 (26.63%) possessed an *APOE* e4 allele. There were n=1,570 dementia cases (0.9%) of which n=634 were AD (0.4%).

Outcomes

Supplementary Table 1 shows associations between *APOE* e4 genotype and multiple worse outcomes: dementia (odds ratio[OR]=3.27 for e4 vs. not), AD (OR=5.06), log Tower rearranging score (beta = -0.07 SDs for e4 vs. not), Matrix Reasoning (-0.11 SDs), frontal lobe GM (-0.05), hippocampal volume (-0.10), overall GM (-0.06), log TMT total time (0.037) and Digit symbol (-0.075; lowest P-value = 0.038). KL heterozygosity (vs. not) was associated with gFrontal only (-0.041 SDs; P=0.043). There were no statistically significant *APOE*/KL interactions. As sensitivity analyses all models were re-run: unadjusted then covariates added incrementally; excluding people with concurrent neurological conditions¹²; and using the full sample (aged <60). These made no difference to the results.

Discussion

A recent study by Belloy et al.³ reported a protective modifying effect of KL heterozygosity on *APOE* e4 genotype's conferred risk on cognitive impairment and dementia, in a collation of longitudinal, AD and amyloid-beta cohorts totalling N=24,743. Using unrelated UK Biobank data we tested whether a similar effect could be seen in multiple outcomes: AD/all-cause dementia vs. not, and non-demented cognitive and structural brain MRI phenotypes known to underlie cognitive decline. Participants were ≥60 years as per Belloy et al. We identified individual *APOE* and KL genotype/outcome associations but no interactions, against our hypothesis. There could be an underestimation of true effect due to cognitive test imprecision¹² or generally preserved participant health¹¹. No interaction here vs. Belloy et al.

could reflect the use of different phenotypes: the original study investigated AD case vs. control status, conversion to impairment and amyloid-beta while this study investigated AD status and non-demented cognitive/brain structure values. UK Biobank derived dementia status largely from ICD codes whereas Belloy et al. used clinical and/or pathological ascertainment. This could suggest that the age-dependent changes in KL expression, and interaction with *APOE* status, manifest only beyond at least moderate AD-related neuropathology (e.g. amyloid or tau)¹⁴. The null AD case/control interaction could reflect that UK Biobank is relatively healthy and well-educated. It is possible the UK Biobank participants were not sufficiently old; analysis of longitudinal cognitive and brain imaging data (in independent data) is indicative of more pronounced KL heterozygosity effects particularly into later life¹⁵.

Limitations

This study did not explore an exhaustive list of structural imaging phenotypes. There is some degree of healthy volunteer bias in UK Biobank participants, and probably more so in participants who returned for imaging. Some imaging participants would have been unable to complete scanning due to contraindications related to poorer health, e.g. pacemakers/stents¹¹.

Summary

A recent relatively large-scale study including cohort, case/control longitudinal and amyloid-beta data showed a significant interaction whereby KL genotype modified the well-known *APOE* e4 and dementia association. Using independent cognitive, structural brain and dementia data, we did not support these prior findings; this could reflect some degree of bias or imprecision in UK Biobank participants or phenotypes, or that the interaction while 'true' is contingent on AD-related neuropathology: future studies should investigate this further in deeply-phenotyped cohorts.

Funding

RT is funded by a Baillie Gifford doctoral student fellowship. UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. DJS is supported by an MRC Pathfinder grant.

Role of the funder/sponsor

The funders had no role in study design, data collection or management, analyses or interpretation of the data, nor preparation, review or approval of the manuscript.

Conflict of interest disclosures

None.

Author contributions

Concept and design: DML

Acquisition, analysis, or interpretation of data: DML, RT.

Drafting of the manuscript: DML, RT.

Critical revision of the manuscript for important intellectual content: All co-authors.

Statistical analysis: DML.

Obtained principal study funding: DML, KF.

References

1. Crenshaw DG, Gottschalk WK, Lutz MW, et al. Using Genetics to Enable Studies on the Prevention of Alzheimer's Disease. *Clin Pharmacol Ther.* 2013;93(2):177-185. doi:10.1038/clpt.2012.222
2. Vo HT, Laszczyk AM, King GD. Klotho, the Key to Healthy Brain Aging? *Brain Plast.* Published online 2018. doi:10.3233/bpl-170057
3. Belloy ME, Napolioni V, Han SS, Le Guen Y, Greicius MD. Association of Klotho-VS Heterozygosity with Risk of Alzheimer Disease in Individuals Who Carry APOE4. *JAMA Neurol.* Published online 2020. doi:10.1001/jamaneurol.2020.0414
4. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature.* Published online 2018. doi:10.1038/s41586-018-0579-z
5. Lyall DM, Celis-Morales C, Lyall LM, et al. Assessing for interaction between APOE ε4, sex, and lifestyle on cognitive abilities. *Neurology.* Published online 2019. doi:10.1212/WNL.00000000000007551
6. Lyall DM, Cox SR, Lyall LM, et al. Association between APOE e4 and white matter hyperintensity volume, but not total brain volume or white matter integrity. *Brain Imaging Behav.* Published online 2019. doi:10.1007/s11682-019-00069-9
7. Ferguson AC, Tank R, Lyall LM, et al. Alzheimer's Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769). *J Alzheimer's Dis.* 2020;76(4):1541-1551. doi:10.3233/jad-200338
8. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLoS Med.* 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
9. Wilkinson T, Schnier C, Bush K, et al. Identifying dementia outcomes in UK Biobank:

- 243 a validation study of primary care, hospital admissions and mortality data. *Eur J*
244 *Epidemiol.* 2019;34(6):557-565. doi:10.1007/s10654-019-00499-1
- 245 10. Alfaro-Almagro F, Jenkinson M, Bangerter NK, et al. Image processing and Quality
246 Control for the first 10,000 brain imaging datasets from UK Biobank. *Neuroimage.*
247 Published online October 24, 2017. doi:10.1016/j.neuroimage.2017.10.034
- 248 11. Ferguson AC, Tank R, Lyall LM, et al. Association of systolic blood pressure and body
249 mass index with cognitive and structural brain phenotypes in UK Biobank. *J*
250 *Hypertens.* Published online June 9, 2020. doi: 10.1097/HJH.0000000000002579
- 251 12. Lyall DM, Cullen B, Allerhand M, et al. Cognitive test scores in UK biobank: Data
252 reduction in 480,416 participants and longitudinal stability in 20,346 participants.
253 *PLoS One.* 2016;11(4). doi:10.1371/journal.pone.0154222
- 254 13. Mengel-From J, Soerensen M, Nygaard M, McGue M, Christensen K, Christiansen L.
255 Genetic variants in KLOTHO associate with cognitive function in the oldest old group.
256 *Journals Gerontol - Ser A Biol Sci Med Sci.* Published online 2016.
257 doi:10.1093/gerona/glv163
- 258 14. Neitzel J, Franzmeier N, Rubinski A, et al. KL-VS heterozygosity is associated with
259 reduced tau accumulation and lower memory impairment in Alzheimer's disease KL-
260 VS heterozygosity attenuates downstream effects of amyloid on tau and cognition.
261 *medRxiv.* Published online July 31, 2020:2020.07.29.20164434.
262 doi:10.1101/2020.07.29.20164434
- 263 15. de Vries CF, Staff RT, Harris SE, et al. Klotho, APOEε4, cognitive ability, brain size,
264 atrophy, and survival: a study in the Aberdeen Birth Cohort of 1936. *Neurobiol Aging.*
265 Published online 2017. doi:10.1016/j.neurobiolaging.2017.02.019